- Home
- XERS vs LASR Comparison
XERS vs LASR Comparison
Compare XERS & LASR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- LASR
- Stock Information
- Founded
- XERS 2005
- LASR 2000
- Country
- XERS United States
- LASR United States
- Employees
- XERS N/A
- LASR N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- LASR Semiconductors
- Sector
- XERS Health Care
- LASR Technology
- Exchange
- XERS Nasdaq
- LASR Nasdaq
- Market Cap
- XERS 526.3M
- LASR 454.5M
- IPO Year
- XERS 2018
- LASR 2018
- Fundamental
- Price
- XERS $4.24
- LASR $9.27
- Analyst Decision
- XERS Strong Buy
- LASR Strong Buy
- Analyst Count
- XERS 4
- LASR 4
- Target Price
- XERS $5.75
- LASR $15.13
- AVG Volume (30 Days)
- XERS 2.4M
- LASR 397.2K
- Earning Date
- XERS 03-06-2025
- LASR 05-01-2025
- Dividend Yield
- XERS N/A
- LASR N/A
- EPS Growth
- XERS N/A
- LASR N/A
- EPS
- XERS N/A
- LASR N/A
- Revenue
- XERS $203,070,000.00
- LASR $198,548,000.00
- Revenue This Year
- XERS $20.47
- LASR $9.35
- Revenue Next Year
- XERS $19.35
- LASR $12.33
- P/E Ratio
- XERS N/A
- LASR N/A
- Revenue Growth
- XERS 23.89
- LASR N/A
- 52 Week Low
- XERS $1.69
- LASR $7.94
- 52 Week High
- XERS $4.50
- LASR $14.73
- Technical
- Relative Strength Index (RSI)
- XERS 70.54
- LASR 42.05
- Support Level
- XERS $3.59
- LASR $7.94
- Resistance Level
- XERS $4.50
- LASR $9.95
- Average True Range (ATR)
- XERS 0.25
- LASR 0.60
- MACD
- XERS 0.03
- LASR -0.08
- Stochastic Oscillator
- XERS 72.34
- LASR 42.22
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About LASR nLIGHT Inc.
nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products, which includes semiconductor lasers, fiber lasers, and directed energy products; and Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA.